论文部分内容阅读
目的:研究左炔诺孕酮宫内节育系统(曼月乐)联合散结镇痛胶囊治疗子宫腺肌症的疗效及安全性。方法:160例子宫腺肌症患者随机均分为观察组和对照组各80例。对照组给予散结镇痛胶囊,观察组在对照组基础上加用曼月乐治疗。6个月后,观察两组患者治疗前后痛经、子宫内膜情况,痛经缓解率、月经改善率及病灶缩小率,比较两组疗效和药品不良反应发生情况。结果:治疗后,两组患者的痛经评分均明显降低,子宫内膜明显变薄(P<0.01);且观察组改善效果明显优于对照组(P<0.01)。观察组痛经缓解率、月经改善率及病灶缩小率均明显高于对照组(P<0.01);治疗总有效率91.25%,明显高于对照组的65.00%(P<0.01);两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:曼月乐联合散结镇痛胶囊治疗子宫腺肌症,疗效显著,安全有效,值得临床推广应用。
Objective: To study the efficacy and safety of levonorgestrel intrauterine system (Mirena) in combination with Sanjiezhitong capsule in the treatment of adenomyosis. Methods: 160 patients with adenomyosis were randomly divided into observation group and control group, 80 cases each. The control group was given Sanjie analgesic capsules. The observation group was treated with Mirena on the basis of the control group. After 6 months, the dysmenorrhea, endometrial conditions, the rate of dysmenorrhea, the improvement rate of menstruation and the shrinkage rate of the two groups were observed before and after treatment. The curative effect and adverse drug reactions were compared between the two groups. Results: After treatment, the scores of dysmenorrhea were significantly decreased in both groups, and the endometrium was significantly thinner (P <0.01). The improvement in observation group was better than that in control group (P <0.01). The rate of dysmenorrhea, the rate of menstruation and the rate of lesion lesion in the observation group were significantly higher than those in the control group (P <0.01). The total effective rate was 91.25% in the observation group, which was significantly higher than that in the control group (65.00%, P <0.01) No significant difference in the incidence of response (P> 0.05). Conclusion: Mirena combined Sanjiezhitong Capsule in the treatment of adenomyosis has obvious curative effect, safe and effective, which is worthy of clinical application.